Overcoming challenges associated with chemotherapy treatment in the senior adult population

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 1 SUPPL., 2008, Pages

  Droz, Jean Pierre ^a   Aapro, Matti ^b   Balducci, Lodovico ^c  

^a UNIVERSITÉ LYON 1   (France)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Docetaxel; International Society of Geriatric Oncology (SIOG); Prostate cancer; Senior adult patients

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; NITROSOUREA; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AGING; ANOREXIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DEHYDRATION; DELIRIUM; DEMENTIA; DEMOGRAPHY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKEMIA; LIFE EXPECTANCY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MYELOMA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; POPULATION SURVEILLANCE;

EID: 50349093575     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.005     Document Type: Review

References (62)

1. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website.
2. US Administration on Aging; 2005. Available from: www.aoa.gov/prof/Statistics/online_stat_data/AgePop2050.asp [last accessed April 2, 2008].
3. Commission of the European Communities. Green paper "Confronting demographic change: a new solidarity between the generations". Available from: http://europa.eu.int/eur-lex/lex/LexUriServ/site/en/com/2005/com2005_0094en01.pdf [last accessed April 2, 2008].
4. Aapro M.S., Kohne C.H., Cohen H.J., and Extermann M. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. Oncologist 10 (2005) 198-204
5. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 11 (2005) 437-441
6. Wildiers H., Highley M.S., de Bruijn E.A., and van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42 (2003) 1213-1242
7. Yee K.W., Pater J.L., Pho L., Zee B., and Siu L.L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 21 (2003) 1618-1623
8. Kumar A., Soares H.P., Balducci L., and Djulbegovic B. Treatment efficacy and tolerance in geriatric oncology. J Clin Oncol 24 (2006) 18s [abstract no. 6115]
9. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
10. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25 (2007) 1832-1843
11. Townsley C.A., Selby R., and Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23 (2005) 3112-3124
12. Benson A.B., Pregler J.P., Bean J.A., Rademaker E.W., Eshler B., and Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center Study. J Clin Oncol 9 (1991) 2067-2075
13. DeMichele A., Putt M., Zhang Y., Glick J.H., and Norman S. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 97 (2003) 2150-2159
14. Giordano S.H., Hortobagyi G.N., Kau S.W., Theriault R.L., and Bondy M.L. Breast cancer treatment guidelines in older women. J Clin Oncol 23 (2005) 783-791
15. Yellen S.B., Cella D.F., and Leslie W.T. Age and clinical decision making in oncology patients. J Natl Cancer Inst 86 (1994) 1766-1770
16. Extermann M., Albrand G., Chen H., et al. Are older French patients as willing as older American patients to undertake chemotherapy?. J Clin Oncol 21 (2003) 3214-3219
17. Rossman I. Clinical geriatrics. 2nd ed. (1979), Lippincott, Philadelphia, PA
18. Egorin M.J. Cancer pharmacology in the elderly. Semin Oncol 20 (1993) 43-49
19. Lichtman S.M. Physiological aspects of aging: implications of the treatment of cancer. Drugs Aging 7 (1995) 212-225
20. Cova D., and Balducci L. Cancer chemotherapy in the older patient. In: Balducci L. (Ed). Comprehensive geriatric oncology (2004), Taylor & Francis, Abingdon 463-488
21. Lichtman S.M. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol 3 (2006) 86-93
22. Brenner B.M., Meyer T.W., and Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of glomerular sclerosis in aging, renal ablation and intrinsic renal disease. N Engl J Med 307 (1982) 652-659
23. Lichtman S.M. Chemotherapy in the elderly. Semin Oncol 31 (2004) 160-174
24. McClean A.J., and Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56 (2004) 163-184
25. Schiller J.H., Berry W., Storer B., et al. Phase II trial of amifostine, cisplatin and vinblastine for metastatic non-small lung cancer. Proc Am Soc Oncol 14 (1995) 356 [abstract no. 1084]
26. Sawhney R., Sehl M., and Naeim A. Physiologic aspects of aging: impact on cancer management and decision making. Part 1. Cancer J 11 (2005) 449-460
27. Droz J.P., and Chaladaj. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU 101 Suppl 2 (2008) 23-29
28. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients. Recommendations from the task force on CGA of the International Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
29. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5 (2000) 224-237
30. Goodwin J.S., Satish S., Anderson E.T., et al. Effect of nurse case management on the treatment of older women with breast cancer. J Am Geriatr Soc 51 (2003) 1252-1259
31. McCorkle R., Stumpf N.E., Nuamah I.F., et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48 (2000) 1707-1713
32. Rao A.V., Hsieh F., Feussner J.R., et al. Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A: Biol Sci Med Sci 60 (2005) 798-803
33. Wolfson C., Wofson D.B., Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344 (2001) 1111-1116
34. ten Tije A.J., Verweij J., Carducci M.A., et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23 (2005) 1070-1077
35. Baker S.D., and Grochow L.B. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13 (1997) 169-183
36. Lichtman S.M., and Skirvin J.A. Pharmacology of antineoplastic agents in older cancer patients. Oncology 14 (2000) 1743-1755
37. Extermann M., Bolero I., O'Neill E., et al. Muscle weakness is a significant problem with older patients receiving chemotherapy. J Clin Oncol 24 (2006) 18s. [abstract no. 8545]
38. National Comprehensive Cancer Network. NCCN oncology guidelines 2007: prostate cancer. Available from: www.nccn.org [last accessed April 2, 2008].
39. American Cancer Society. Cancer facts and figures 2005. Atlanta: American Cancer Society; 2005.
40. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
41. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
42. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
43. de Wit R., Eisenberger M.A., Tannock I.F., Yateman N., and Yao S.-L. A multicenter phase III comparison of docetaxel + prednisone (P) and mitoxantrone (MTZ) + P in patients with androgen-independent prostate cancer (AIPC): secondary analysis of survival in patient subgroups. Ann Oncol 15 Suppl 3 (2004) [abstract no. 4]
44. Anderson J., Van Poppel H., Bellmunt J., Miller K., Droz J.P., and Fitzpatrick J.M. Chemotherapy for older patients with prostate cancer. BJU Int 99 (2007) 269-273
45. Beer T.M., Berry W., Wersinger E.M., and Bland L.B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2 (2003) 167-172
46. Droz JP, Balducci L, Bolla M, et al. SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men. Poster presented at the 29th congress of the Société International d'Urologie (SIU 2007); 2007.
47. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 (2007) 1101-1115
48. Woodard S., Nadella P.C., Kotur L., Wilson J., Burak W.E., and Shapiro C.L. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias?. Cancer 98 (2003) 1141-1149
49. Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
50. Muss H.B., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293 (2005) 1073-1081
51. Loibl S., Von Munckwitz G., Elling D., et al. Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. J Clin Oncol 24 (2006) 18s [abstract no. 18509]
52. Hurria A., Hurria A., Zuckermann E., et al. A prospective longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc 54 (2006) 1119-1124
53. Livi L., Paiar F., Saiera C., et al. Breast cancer in the elderly: treatment of 1500 patients. Breast J 12 (2006) 353-359
54. Muss H.B., Berry D.A., Cirrincione C., et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 25 (2007) 3699-3704
55. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (2003) 3201-3206
56. Yoshimura N., Kudoh S., Kimura T., Mitsuoka S., and Hirata K. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 24 (2006) 18s [abstract no. 17013]
57. Goto K., Nishikawa Y., Saijo N., et al. The Four Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): a subgroup analysis in elderly patients. J Clin Oncol 24 (2006) 18s [abstract no. 13508]
58. Belani C.P., and Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104 (2005) 2766-2774
59. Jessup J.M., Stewart A., Greene F.L., and Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294 (2005) 2703-2711
60. Schrag D., Cramer L.D., Bach P.B., and Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93 (2001) 850-857
61. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001) 1091-1097
62. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091